Abstract:
To investigate the effects of hydralazine combined with nitrate on serum levels of Adropin and brain
natriuretic peptide (BNP), left ventricular remodeling and prognosis in patients with chronic heart failure (CHF). 126
CHF patients were divided into control group (n=13, sodium nitroprusside) and combined treatment group (n=63,
sodium nitroprusside + hydralazine). Serum Adropin and BNP levels and left ventricular mass index (LVMI) of patients
before treatment and 10 days after treatment were recorded, so did patient’s end-point events. It was found that compared
with those before treatment, the serum levels of Adropin, BNP, and LVMI in combined group and control group after 10
days of treatment were lower (P<0.05). The end-point event rate in the combined group was 19.05% (12/63). The serum
levels of Adropin, BNP, and LVMI in the combined group with end-point events were higher than those of patients
without end-point events (P<0.05). Spearman correlation analysis showed that serum levels of Adropin and BNP were
positively correlated with LVMI and the end-point events rate (P<0.05). To sum up, hydralazine combined with sodium
nitroprusside treatment can effectively reduce serum Adropin and BNP levels, and the risk of left ventricular remodeling
and poor prognosis in patients with CHF
